Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy

Recruiting now · Phase 2

Conditions studied: Progression-Free Survival

In brief

To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin

Key facts

Study ID

NCT06826092

Run by

Kaohsiung Medical University Chung-Ho Memorial Hospital

People needed

110

Starts

2022-10-31

Expected to finish

2025-12-31

Last updated by the study team

2025-02-13

Who can join

Age: 20 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged between 20 and 90 years old
• Patients diagnosed with metastatic colorectal cancer who is going to receive FOLFIRI chemotherapy
• Female must not be planning to become pregnant or breastfeeding, and not pregnant at any point during treatment. (Contraception is required to participate in this trial)
• Those without major physiological diseases (example of major cardiovascular disease is acute myocardial infarction; example of major cerebrovascular disease is acute stroke, malignant hypertension, acute kidney failure, acute liver failure)
• Those who are not allergic to the relevant drugs required for the test
• Those who can follow the doctor's order to take the medicine
• Subjects must be willing to sign the consent form
• Blood sugar level above 80 mg/dL

You may not qualify if…

• Subjects who meet any of the following exclusion conditions are not allowed to join the trial
• Patients other than the above-mentioned main inclusion criteria.
• Non-native speakers
• Known allergy to metformin or any of its components.
• Severe instability in diabetes (ketoacidosis).
• Blood sugar level lower than 80 mg/dL
• Heart failure, respiratory insufficiency.
• inadequate hematopoietic function defined as below:
• hemoglobin < 9 g/dL;
• absolute neutrophil count (ANC) < 1,500/mm3;
• platelet count < 100,000/mm3;
• inadequate organ functions defined as below:
• total bilirubin > 2 times upper limit of normal (ULN);
• hepatic transaminases (ALT and AST) > 2.5 x ULN;
• creatinine > 1.5 x ULN;

Where it is running

• Chung-Ho Memorial Hospital, Kaohsiung Medical University: — Kaohsiung City, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.